At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 282 enrolled
Drug / intervention
ricolinostat +1 moredrug
Likely dose
ricolinostat 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy
In Brief
A Phase 2 clinical trial evaluating ricolinostat and Placebo for Painful Diabetic Peripheral Neuropathy. Completed, enrolled 282 participants across 35 sites.
Detailed Summary
This is a randomized, double-blind, 2-arm, parallel group study of up to 274 evaluable patients designed to evaluate the safety and efficacy of the histone deacetylase 6 (HDAC6) inhibitor ricolinostat for painful DPN.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPainful Diabetic Peripheral Neuropathy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartDec 2020
Primary CompletionOct 2022
Study CompletionApr 2023
TodayJul 2026
First PostedJun 5, 2017
Enrollment StartDec 7, 2020
Primary CompletionOct 31, 2022
Study CompletionApr 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.1 years ago
Interventions
ricolinostatdrug
120 mg per dose in 12 mL liquid formulation
Placebodrug
12 mL liquid formulation placebo